ARTICLE | Company News

Regeneron gains on Eylea sales growth

August 4, 2015 11:36 PM UTC

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) rose $26.67 to $580.94 on Tuesday after reporting $655 million in U.S. sales of Eylea aflibercept in 2Q15, up 58% from $415 million in 2Q14. On the earnings call, SVP Commercial Robert Terifay attributed much of the growth to uptake in diabetic macular edema (DME) patients. FDA approved Eylea in July 2014 to treat DME and in March 2015 to treat diabetic retinopathy in DME patients.

The company raised its 2015 Eylea U.S. net sales growth guidance to 45-50% from 30-35%. Bayer (Xetra:BAYN) has ex-U.S. rights to the human fusion protein that binds all forms of VEGF-A and placental growth factor ( PGF; PlGF). ...